Trevi Therapeutics (TRVI) Non Operating Income (2018 - 2025)
Trevi Therapeutics (TRVI) posted quarterly Non Operating Income of $1.9 million for Q4 2025, up 123.7% year-over-year from $844000.0 in Q4 2024, and down 10.05% quarter-over-quarter from $2.1 million in Q3 2025.
Trevi Therapeutics (TRVI) Non Operating Income (2018 - 2025) Analysis & Trends
Trevi Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.9 million for Q4 2025.
- In Q4 2025, Non Operating Income rose 123.7% year-over-year to $1.9 million; the TTM figure through Dec 2025 stood at $6.2 million (up 73.9% YoY), while the FY2025 annual figure was $6.5 million, up 81.55% from the prior year.
- Non Operating Income for Q4 2025 stood at $1.9 million, down from $2.1 million in the prior quarter.
- The five-year high for Non Operating Income was $2.2 million in Q4 2022, with the low at -$297000.0 in Q1 2021.
- The 5-year median for Non Operating Income is $996000.0 (2024), against an average of $884105.3.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income tumbled 11900.0% in 2022, then surged 28775.0% in 2023.
- Trevi Therapeutics' Non Operating Income stood at $1.2 million in 2021, then jumped by 73.35% to $2.2 million in 2022, then tumbled by 47.52% to $1.1 million in 2023, then dropped by 25.31% to $844000.0 in 2024, then soared by 123.7% to $1.9 million in 2025.
- Business Quant data shows TRVI's Non Operating Income at $1.9 million in Q4 2025, $2.1 million in Q3 2025, and $1.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.89 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Dec 31, 2024 | 844,000.00 |
| Sep 30, 2024 | 814,000.00 |
| Jun 30, 2024 | 929,000.00 |
| Mar 31, 2024 | 996,000.00 |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.16 Mn |
| Dec 31, 2022 | 2.15 Mn |
| Sep 30, 2022 | 132,000.00 |
| Jun 30, 2022 | -236,000.00 |
| Mar 31, 2022 | 4,000.00 |
| Dec 31, 2021 | 1.24 Mn |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | -297,000.00 |
| Dec 31, 2020 | -461,000.00 |